The Morisky Medication Adherence Scales (MMAS) are a pair of clinically-validated questionnaires that assess patient adherence. They provide insights that can drive tailored interventions and lead to improved health outcomes.
The CertiScan® Adherence Platform is now the exclusive digital delivery service for the 4-item (MMAS-4) and 8-item (MMAS-8) Morisky scales. Thanks to CertiScan®’s powerful industry-leading capabilities, the MMAS can be filled out, analyzed, and actioned in ways that were previously impossible.
Inappropriate medication use is widespread in clinical research. This can harm individual participant outcomes, jeopardize trial outcomes, and cause hidden errors that are only discovered post market or after publishing (such as a poorly titrated dosage or undiscovered side effect).
Our solutions make it easy to detect and treat these harmful issues. Many protective features are automatic, such as mobile reminders, misuse alerts, targeted coaching.Shorter trials that reach their endpoints more quickly can gain weeks or months of additional patent protection. This can amount to substantial additional revenue.
Our solutions help studies reach last dose, last participant sooner.Clinical trials are becoming increasingly complex and expensive. Certain activities in a protocol seem straightforward on paper, but in practice can translate into dozens of hours of site work.
Use our solutions to help eliminate needless overhead and streamline processes.New, technology-first strategies are transforming clinical trials. DCTs, participant diversity initiatives, and AI tools are changing from “nice-to-haves” into “must-haves”.
Our solutions are modern tools for modern trials that can help researchers and other stakeholders gain and maintain an advantage.
Background: Non-adherence to prescription medications is exhibited by approximately 50% of patients and is…
Read More
PRESS RELEASE May 6, 2024 – New York, NY — Information Mediary Corp (IMC)…
Read More